


In the Claims:

Please amend claims 1, 2, 6, and 11-13. Please cancel claims 3-5, 7, 10, 15, 17, 19 and 42 without prejudice, being drawn to non-elected inventions. Claims 23, 30-31 and 35-40 are provisionally withdrawn without prejudice, subject to rejoinder. Please add new Claim 45.

1. (Currently amended) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

R<sup>3</sup> is selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C<sub>0</sub>-C<sub>3</sub>.

2. (Currently amended) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

$R^1$  and  $R^2$  are independently selected from the group consisting of  $-OR'$ ,  $-SR'$ ,  $-NR'R'$ ,  $-NO_2$ ,  $-CN$ ,  $-C(O)R'$ ,  $-C(O)OR'$ ,  $-C(O)NR'R'$ ,  $-C(NR')NR'R'$ , trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each  $R'$  is independently selected from the group consisting of  $-H$ , alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

$R^3$  is selected from the group consisting of  $-H$ ,  $-OR'$ ,  $-SR'$ ,  $-NR'R'$ ,  $-NO_2$ ,  $-CN$ ,  $-C(O)R'$ ,  $-C(O)OR'$ ,  $-C(O)NR'R'$ ,  $-C(NR')NR'R'$ , trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each  $R'$  is independently selected from the group consisting of  $-H$ , alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of  $C_0-C_3$ .

3. (Cancel) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

$R^1$  and  $R^2$  are independently selected from the group consisting of  $-H$ ,  $-OR'$ ,  $-SR'$ ,  $-NR'R'$ ,  $-NO_2$ ,  $-CN$ ,  $-C(O)R'$ ,  $-C(O)OR'$ ,  $-C(O)NR'R'$ ,  $-C(NR')NR'R'$ , trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each  $R'$  is independently selected from the group consisting of  $-H$ , alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C<sub>0</sub>-C<sub>4</sub>.

4. (Cancel) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C<sub>0</sub>-C<sub>4</sub>.

5. (Cancel) A compound having the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein


R' is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C<sub>0</sub>-C<sub>4</sub>.

6. (Currently amended) A compound having the formula:

- 4 -

Attorney Docket No.: NRNZ-01048US1 DBB  
DBB/NRNZ/1048US1/1048US1.105.doc




or a pharmaceutically acceptable salt or ~~hydrate~~ thereof, wherein

$R^1$  is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C<sub>0</sub>-C<sub>4</sub>.


7. (Cancel) A compound having the formula:



or a pharmaceutically acceptable salt or ~~hydrate~~ thereof, wherein

R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl.

8. (Cancel) A compound having the formula:



or a pharmaceutically acceptable salt or ~~hydrate~~ thereof, wherein

R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO<sub>2</sub>, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl.

9. (Previously presented) The compound of claim 1 where R<sup>1</sup> = -COOH and R<sup>2</sup> = -(CH<sub>2</sub>)<sub>2</sub>-COOH.
10. (Cancel) The compound of claim 3 where R<sup>1</sup> = -CH(COOH)-(CH<sub>2</sub>)<sub>2</sub>-COOH.
11. (Currently amended) The compound of claim 1 where R<sup>3</sup> = methyl ~~or Formula 3 where R<sup>2</sup> = methyl.~~
12. (Currently amended) The compound of claim 1 where R<sup>3</sup> = allyl ~~or Formula 3 where R<sup>2</sup> = allyl.~~
13. (Currently amended) The compound of claim 1 ~~or Formula 3~~ where X = -(CH<sub>2</sub>)<sub>3</sub>-.
14. (Previously presented) The compound of claim 1 where X = -(CH<sub>2</sub>)<sub>2</sub>-.
15. (Cancel) The compound of claim 3 where X = -(CH<sub>2</sub>)<sub>4</sub>-.
16. (Previously presented) The compound of claim 1 where X = -CH<sub>2</sub>-CH=CH-, (where the CH<sub>2</sub> of X is adjacent to the carbon attached to the NH<sub>2</sub> group).

- 6 -

Attorney Docket No.: NRNZ-01048US1 DBB  
DBB/NRNZ/1048US1/1048US1.105.doc

17. (Cancel) The compound of claim 3 where  $X = -CH_2-CH=CH-CH_2-$ .
18. (Previously presented) The compound of claim 1 where  $R^1 = -COOH$ ;  $R^2 = -(CH_2)_2-COOH$ ;  $R^3 = H$ ;  $X = -(CH_2)_3-$ .
19. (Cancel) The compound of claim 3 where  $R^1 = -CH(COOH)-(CH_2)_2-COOH$ ;  $R^2 = H$ ;  $X = -(CH_2)_4-$ .
- 20-22. (Cancel)
23. (Withdrawn) A method of treating a patient to protect neurons otherwise destined to degenerate or die as a result of an injury or disease, comprising administering to a patient an effective amount of one or more compounds of compounds of claim 1.
- 24-29. (Cancel)
30. (Withdrawn and amended) The method of claim 23, wherein the disease is selected from the group consisting of Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, peripheral neuropathy, spinal muscular atrophy, Creutzfeldt-Jakob disease, AIDS dementia, progressive supranuclear palsy, myelinopathia centralis diffusa (vanishing white matter disease), chronic neurodegenerative disease, Down's syndrome, leukoencephalopathy, neuroblastoma, an inflammatory condition, epilepsy, and Schilder's disease.
31. (Withdrawn and amended) The method of claim 23, wherein the injury or disease is a result of one or more conditions selected from the group consisting of ~~neuroblastoma~~, head injury, traumatic brain injury, stroke, ischemic injury, hypoxic injury, reperfusion injury, ~~epilepsy~~, cardiac artery bypass graft surgery, toxin damage, radiation damage and asphyxia.
- 32-34. Cancel.

35. (Withdrawn and amended) A The method of claim 23, wherein at least one other anti-apoptotic, anti-necrotic or neuroprotective agent is administered.

36. (Withdrawn) The method of claim 23, further comprising administering another agent selected from the group consisting of insulin-like growth factor-I [IGF-I], insulin-like growth factor-II [IGF-II], transforming growth factor- $\beta$ 1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding protein, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10 and FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 [BMP-2], glial-cell line derived neurotrophic factor, activity-dependant neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin,  $\alpha$ -interferon,  $\beta$ -interferon,  $\gamma$ -interferon, consensus interferon, TNF- $\alpha$ , clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue [ORG 2766], dizolcipine [MK-801], selegiline, a glutamate antagonist, an AMPA antagonist and an anti-inflammatory agent.

37. (Withdrawn) The method of claim 36 wherein said glutamate antagonist is selected from the group consisting of NPS1506, GV1505260, MK-801 and GV150526.

38. (Withdrawn) The method of claim 36 wherein said AMPA antagonist is selected from the group consisting of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070 and LY300164.

39. (Withdrawn) The method of claim 36, wherein said anti-inflammatory agent is selected from the group consisting of an anti-MAdCAM-1 antibody and an antibody against an integrin  $\alpha$ 4 $\beta$ 1 receptor and an integrin  $\alpha$ 4 $\beta$ 7 receptor.

40. (Withdrawn) The method of claim 39 wherein said anti-MAdCAM-1 antibody is MECA-367.

41. (Withdrawn) The method of claim 23 where the compound is (2S, 3'S, 8'R, 11'S) 2-[[[3'-Amino-1'-aza -2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate salt.
42. (Withdrawn) The method of claim 23 where the compound is (2S, 9'R, 12'S)-2-[[[1',4'-Diaza-2'-oxobicyclo[7.3.0]dodecyl)-12'-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate.
43. (Withdrawn) The method of claim 23, wherein said condition is hypoxic ischemia.
44. (Withdrawn) The method of claim 23, wherein said condition is neurotoxicity.

Please add the following new claim.

45. (New) The compound of Claim 1, where the compound is (2S, 3'S, 8'R, 11'S) 2-[[[3'-Amino-1'-aza -2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid.